Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg

NCT02424019 is registered in ClinicalTrials.gov with Alimera Sciences as lead sponsor.

NCT NCT02424019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02424019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg
Lead sponsor
Alimera Sciences
Phase
Phase 4
Overall status
Completed
Start date
May 6, 2015
Completion date
July 31, 2020
Enrollment
153 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema (dme)